The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of a novel AI-based digital pathology (CHAI) biomarker with progression free survival (PFS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).
 
Georges Gebrael
No Relationships to Disclose
 
Vrishab Krishna
Employment - Valar Labs
 
Nicolas Sayegh
No Relationships to Disclose
 
Chadi Hage Chehade
No Relationships to Disclose
 
Zeynep Irem Ozay
No Relationships to Disclose
 
Snehal Sonawane
Employment - Valar Labs
Other Relationship - Collage of American Pathologists
 
Viswesh Krishna
Employment - Valar Labs
 
Daniel Miller
Employment - Valar Labs
 
Waleed Abuzeid
Employment - Valar Labs
 
Siddhant Shingi
Employment - Valar Labs
 
Louis Vaickus
Consulting or Advisory Role - Valar Labs
 
Damir Vrabac
Employment - Valar Labs
 
Anirudh Joshi
Employment - Valar Labs
 
Vivek Nimgaonkar
Employment - Valar labs
 
Umang Swami
Consulting or Advisory Role - Adaptimmune; Astellas Pharma; AstraZeneca; Exelixis; Gilead Sciences; Imvax; Janssen Scientific Affairs; Pfizer; Sanofi; Seagen
Research Funding - Exelixis (Inst); Janssen (Inst); lava therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); ORIC Pharmaceuticals (Inst); Seagen (Inst); Seattle Genetics/Astellas (Inst)
 
Deepika Sirohi
No Relationships to Disclose
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer